Astec LifeSciences Limited
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- ₹27.77 billion
- Book Value:
- Revenue TTM:
- ₹5.87 billion
- Operating Margin TTM:
- Gross Profit TTM:
- ₹1.87 billion
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Astec LifeSciences Limited had its IPO on under the ticker symbol ASTEC.
The company operates in the Basic Materials sector and Agricultural Inputs industry. Astec LifeSciences Limited has a staff strength of 551 employees.
Shares of Astec LifeSciences Limited opened at ₹1431 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹1368 - ₹1443.95, and closed at ₹1371.55.
This is a -3.68% slip from the previous day's closing price.
A total volume of 19,533 shares were traded at the close of the day’s session.
In the last one week, shares of Astec LifeSciences Limited have slipped by -2.37%.
Astec LifeSciences Limited's Key Ratios
Astec LifeSciences Limited has a market cap of ₹27.77 billion, indicating a price to book ratio of 8.3858 and a price to sales ratio of 4.2818.
In the last 12-months Astec LifeSciences Limited’s revenue was ₹5.87 billion with a gross profit of ₹1.87 billion and an EBITDA of ₹529.57 million. The EBITDA ratio measures Astec LifeSciences Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Astec LifeSciences Limited’s operating margin was 3.52% while its return on assets stood at 2.9% with a return of equity of 6.27%.
In Q2, Astec LifeSciences Limited’s quarterly earnings growth was a positive 0% while revenue growth was a negative 22.5%.
Astec LifeSciences Limited’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at ₹3.04 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Astec LifeSciences Limited’s profitability.
Astec LifeSciences Limited stock is trading at a EV to sales ratio of 4.5731 and a EV to EBITDA ratio of 20.7807. Its price to sales ratio in the trailing 12-months stood at 4.2818.
Astec LifeSciences Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 49.23%.
Balance sheet and cash flow metrics
- Total Assets
- ₹9.79 billion
- Total Liabilities
- ₹5.26 billion
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Astec LifeSciences Limited ended 2023 with ₹9.79 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹9.79 billion while shareholder equity stood at ₹4.19 billion.
Astec LifeSciences Limited ended 2023 with ₹0 in deferred long-term liabilities, ₹5.26 billion in other current liabilities, 196057000.00 in common stock, ₹4.00 billion in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹4.73 million and cash and short-term investments were ₹27.54 million. The company’s total short-term debt was ₹0 while long-term debt stood at ₹108.63 million.
Astec LifeSciences Limited’s total current assets stands at ₹4.99 billion while long-term investments were ₹0 and short-term investments were ₹5.96 million. Its net receivables were ₹1.55 billion compared to accounts payable of ₹1.77 billion and inventory worth ₹2.95 billion.
In 2023, Astec LifeSciences Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Astec LifeSciences Limited paid ₹0.49 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Astec LifeSciences Limited stock is currently trading at ₹1371.55 per share. It touched a 52-week high of ₹2283.0308 and a 52-week low of ₹2283.0308. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹1329.66 and 200-day moving average was ₹1455.63 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 7044.3% of the company’s stock are held by insiders while 1192% are held by institutions.
Frequently Asked Questions About Astec LifeSciences Limited
Similar Industry Stocks (Agricultural Inputs)
Astec LifeSciences Limited, together with its subsidiaries, manufactures, distributes, and sells agrochemical active ingredients and pharmaceutical intermediates in India. Its products include triazole fungicides, heterocyclic herbicides, sulfonyl urea herbicides, synthetic pyrethroids, alkyl and aryl magnesium halides, mixed metal halides, and silane derivatives; fluorinated aromatic, aliphatic, and heterocyclic intermediates; fluorinated aromatic amines, pyridine derivatives, aromatic carboxylic acids, benzyl alcohols, ketones and benzophenones, and heterocyclic mercaptans; heterocyclic mercaptans, thiopyrimidines, and aromatic mercaptans; heterocyclic sulfonyl chlorides, sulphonamides, and carbamates; thiourium salts, alkyl and aryl chloroformates, substituted pyrimidine diones, and pyrazolones; and substituted 1,2- and 1,3- pyrimidines. The company’s products also comprise pyrazolyl aromatic ketones, morpholine derivatives, aromatic azo compounds, substituted triazines, imidate ethers, mesylated intermediates, substituted epoxides, ketals and bromo ketals, aromatic and aliphatic ethers, cyclopropyl ethers, cyclopropyl aldehydes and ketones, conjugated ketones, acetophenone derivatives, pinacolone derivatives, aliphatic and aromatic carboxylic acids, aliphatic and aromatic acid chlorides, halogenated and non-halogenated anhydrides, aliphatic alkenes, and halo alkanes; and aliphatic and aromatic brominated derivatives, cyanides, esters, carboxamides, amines, and alcohols and diols. It also exports its products. The company was incorporated in 1994 and is based in Mumbai, India. Astec LifeSciences Limited is a subsidiary of Godrej Agrovet Limited.